Company

Sino Biopharmaceutical's Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation
Chia Tai Tianqing PharmaceuticalClinical trial results

Sino Biopharmaceutical’s Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation

Sino Biopharmaceutical Limited (HKG: 1177) announced in a voluntary filing that clinical results for TQ‑A3334, an oral TLR7 agonist independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd.…

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Merck Inaugurates ADVANCE Research Facility in West Point, Pennsylvania – AI‑Powered Automation Hub to Accelerate Global Drug Development

Merck Inaugurates ADVANCE Research Facility in West Point, Pennsylvania – AI‑Powered Automation Hub to Accelerate Global Drug Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China
AmgenNASDAQ: AMGN

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

BiosunpharmaProduct approvals

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Dianthus TherapeuticsHKG: 9887

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

ADC / XDCClinical trial approval / initiation

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Show More